Sequenta Secures $20M For Immune Therapeutics
South San Francisco-based biotechnology developer Sequenta has raised $20M in a Series C funding, the firm said today. Sequenta said the round was led by Foresite Capital Management, and also included Mohr Davidow Ventures and Index Ventures. Sequenta said that Jim Tananbaum of Foresite Capital has joined the company's board as part of the funding. The funding will go towards commercial scale up and clinical validation of its lead product, aimed at diagnosis of patients with leukemia or lymphoma.
posted on Tuesday, July 2, 2013 (Link to more information)
Related companies:
Sequenta, Inc.
Related stories:
> Sequenta Raises $13M
> Sequenta Acquired By Adaptive Bio
> Immune Design Gets $49M For Cancer Therapy
> Adheron Therapeutics Acquired By Roche For $105M
> Merck Buys Sirna Therapeutics
silicontap.com Home